Therapeutic Asset Ratings

176 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Daunorubicin Non-Small Cell Lung Cancer	Pfizer	P3	B (58)
Ibrutinib Non-Small Cell Lung Cancer	Montefiore Medical Center	P3	B (58)
Oritinib Non-Small Cell Lung Cancer	Nanjing Sanhome Pharmaceutical, Co., Ltd.	P3	B (58)
Selpercatinib Non-Small Cell Lung Cancer	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	P3	B (58)
Sotorasib Non-Small Cell Lung Cancer	National Cancer Institute (NCI)	P3	B (58)
sys6010 Non-Small Cell Lung Cancer	CSPC Megalith Biopharmaceutical Co.,Ltd.	P3	B (58)
Fludarabine Non-Small Cell Lung Cancer	University of Pennsylvania	P3	B (57)
Entrectinib Non-Small Cell Lung Cancer	Fudan University	P3	B (56)
Binimetinib Non-Small Cell Lung Cancer	Peking University Cancer Hospital & Institute	P2	B (56)
Telisotuzumab Adizutecan Non-Small Cell Lung Cancer	AbbVie	P2/3	B (56)
mk-3475 Non-Small Cell Lung Cancer	Merck Sharp & Dohme LLC	P3	CCC (55)
Glumetinib Non-Small Cell Lung Cancer	Shanghai JMT-Bio Inc.	P3	CCC (54)
hs-20093 Non-Small Cell Lung Cancer	Hansoh BioMedical R&D Company	P3	CCC (54)
Immunoglobulin G4 [221-proline], anti-(human programmed cell death protein 1) (human monoclonal SG001 ?4-chain), disulfide with human monoclonal SG001 ?-chain, dimer Non-Small Cell Lung Cancer	CSPC Megalith Biopharmaceutical Co.,Ltd.	P3	CCC (54)
PEGASPARGASE Non-Small Cell Lung Cancer	Pfizer	P3	CCC (54)
rc148 Non-Small Cell Lung Cancer	RemeGen Co., Ltd.	P3	CCC (54)
sy-5007 Non-Small Cell Lung Cancer	Shouyao Holdings (Beijing) Co. LTD	P3	CCC (54)
Immunoglobulin G1-kappa, anti-[Homo sapiens MET (met proto-oncogene, hepatocyte growth factor (HGF) receptor, HGFR, scatter factor (SF) receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-met, papillary renal cell carcinoma 2, RCCP2)] and anti-[Homo sapiens EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], Homo sapiens monoclonal antibody, bispecific Non-Small Cell Lung Cancer	Betta Pharmaceuticals Co., Ltd.	P2	CCC (54)
Encorafenib Non-Small Cell Lung Cancer	Peking University Cancer Hospital & Institute	P2	CCC (53)
Denosumab Non-Small Cell Lung Cancer	China Medical University, China	P3	CCC (52)
bgb324 Non-Small Cell Lung Cancer	BerGenBio ASA	P2	CCC (52)
Budigalimab Non-Small Cell Lung Cancer	AbbVie	P2/3	CCC (52)
hs-20117 Non-Small Cell Lung Cancer	Jiangsu Hansoh Pharmaceutical Co., Ltd.	P2/3	CCC (52)
Iza-Bren Non-Small Cell Lung Cancer	M.D. Anderson Cancer Center	P2/3	CCC (52)
Shr-8068 Non-Small Cell Lung Cancer	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	P2/3	CCC (52)

Showing 26 to 50 of 176 assets

PreviousPage 2 of 8Next